Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYSA-7: KYV-101 in Refractory Progressive Multiple Sclerosis
NCT06384976Phase 2Active, not recruiting
- Sponsor
- Kyverna Therapeutics
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in primary progressive multiple sclerosis (PPMS), secondary-progressive multiple sclerosis (SPMS), sponsored by Kyverna Therapeutics. Started Sep 2024; status: active, not recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06384976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384976.